Science

Science

The Solution

A simpler, more effective path to consistent galactosylation

Galixa™ integrates into existing CHO cell platforms in two straightforward steps.
The result is homogeneous, maximized galactosylation across mAbs, biscpecifics, and ADCs.
Step 1

COSMC Knockout

"Free up the raw material"

Removes the competing enzyme that diverts galactose precursors, creating abundant substrate for the next engineering step.
Step 2

Beta4GaIT Overexpression

"Scale up the machinery"

Amplifies the enzyme responsible for adding galactose to antibody subunits – driving consistent, near-complete galactosylation across all product lots.

Platform Compatibility

  • Extends biologics patent & regulatory exclusivity
  • No new bioreactor or media required
  • mAbs bispecifics · ADCs · Fc-fusions

Antibody Outcome

  • Optimize function
  • Enhance stability
  • Reduce immunogenicity
  • Control clinical (PK/PD) profile
  • Reduces high mannose (Man5)
  • Reduce batch-to-batch variability